A twin pregnancy with a hydatidiform mole and a coexisting live fetus: prenatal diagnosis, treatment, and follow-up

Antonio Braga¹, Bruna Obeica¹, Heron Werner², Sue Yazaki Sun³, Joffre Amim Júnior¹, Jorge Rezende Filho¹, Edward Araujo Júnior³

¹ Rio de Janeiro Trophoblastic Disease Center, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
² Department of Radiology, Clínica de Diagnóstico por Imagem, Rio de Janeiro, Brazil
³ Department of Obstetrics, Paulista School of Medicine – Federal University of São Paulo, São Paulo, Brazil

Correspondence: Prof. Edward Araujo Júnior, PhD, Rua Belchior de Azevedo, 156 apto. 111 Torre Vitoria, São Paulo – SP, Brazil, CEP 05089-030, tel. +55 11 37965944, e-mail: araujojred@terra.com.br

DOI: 10.15557/JoU.2017.0044

Abstract

Twin molar pregnancy with a hydatidiform mole and a coexisting live fetus is a rare form of gestational trophoblastic disease associated with an increased risk of obstetric complications and poor perinatal outcome. Prenatal diagnosis is essential for couple counseling and follow-up in Tertiary Reference Centers. Magnetic resonance imaging is important for the diagnostic differentiation of placental mesenchymal dysplasia and exclusion of myometrial invasion. Here we present a case of twin molar pregnancy with a hydatidiform mole and a coexisting live fetus diagnosed at gestational week 14 using two-dimensional (2D) and three-dimensional (3D) ultrasound and magnetic resonance imaging. We also describe the obstetric management and postmolar follow-up.

Keywords

twin pregnancy, hydatidiform mole, ultrasound, magnetic resonance imaging, staging

Introduction

Molar pregnancy constitutes a benign spectrum of gestational trophoblastic disease (GTD)¹. The occurrence of GTD in Brazil² is 5–10 times more common than that in the United States and Europe³,⁴. Molar pregnancy is caused by a cytogenetic anomaly in fertilization, and may lead to two clinical forms: a complete and partial hydatidiform mole⁵. The clinical significance of this reproduction is the possibility of evolution to gestational trophoblastic neoplasia (GTN), which may cause maternal death if not properly treated⁶⁻⁸.

A particular form of the clinical presentation of GTD is a twin molar pregnancy with a hydatidiform mole and a coexisting live fetus. This condition is rare, with an estimated incidence of 1 to 20,000–100,000 pregnancies⁹. Although the etiopathogenesis of this type of gestation is unclear, several studies have found a correlation of twin pregnancy with a hydatidiform mole and a coexisting live fetus with clinical complications typical of late hydatidiform moles more frequently than in single moles, thus increasing the risk of potentially fatal complications and a near miss⁶,⁷.

In this study we describe the clinical, diagnostic, and therapeutic aspects of a case of twin pregnancy with hydatidiform mole and a coexisting live fetus.

Case report

The patient is a 37-year-old Brazilian, white, married woman in her second gestation, with a history of spontaneous abortion. The blood hCG level of the patient was 171 IU/L, measured at a family practice clinic. The patient sought emergency obstetric care at a local community hospital with the complaint of vaginal bleeding, and transvaginal ultrasonography showed a gravid uterus with a single fetus with crown–rump length (CRL)
of 34 mm, confirming a gestational age of 10 weeks. The uterus presented a thickened decidua (141 × 44 × 79 mm) that occupied the uterine fundus and body, and a heterogeneous ultrasound pattern, characterized by small anechoic formations suggestive of molar pregnancy. On the same day, and at the same local hospital, the hCG level measurement was repeated, and a result of 9,986 IU/L was obtained. Since there was a suspicion of GTD, the patient was referred to the Rio de Janeiro Trophoblastic Disease Center at the Federal University of Rio de Janeiro (UFRJ).

The patient complained of pelvic pain, uncontrollable vomiting and mild transvaginal bleeding. On clinical examination the patient was pale (2+/4+), hypertensive (blood pressure of 150 × 90 mmHg) and tachycardic (heart rate of 100 bpm), with the uterine fundus enlarged for the gestational age (22 cm). The level of hCG was measured again the next day, and it was 1,881,508 IU/L. A two-dimensional (2D) ultrasound showed an enlarged uterus filled with a heterogeneous pattern and a live fetus of a gestational age compatible with 14 weeks (Fig. 1).

A three-dimensional (3D) ultrasound in HDlive rendering mode showed a realistic image of a fetus coexisting with a hydatidiform mole (Fig. 2). Magnetic resonance imaging (MRI) was performed to better determine the relationship between the living fetus and the hydatidiform mole. T1- and T2-weighted MRI images showed an enlarged uterus filled with amorphous heterogeneous material coexisting with a live fetus (Fig. 3), along with a distinct junction between the myometrium and the molar tissue but without evidence of myometrial invasion. These findings were compatible with the diagnosis of a twin pregnancy with a complete hydatidiform mole and a coexisting live fetus.
A twin pregnancy with a hydatidiform mole and a coexisting live fetus: prenatal diagnosis, treatment, and follow-up

After couple counseling, the gestation was maintained, and chorionic villus biopsy and amniocentesis revealed a diploid placenta (46 XX) and a diploid fetus (46 XY). The patient was admitted into obstetric emergency unit with complaints of severe vaginal bleeding, discharge of vesicles (Fig. 4), and severe pre-eclampsia (blood pressure of 170 × 110 mmHg, creatinine of 1.2 mg/dL, AST of 90 U/L). The hCG level on that day was 2,220,890 IU/L, and magnesium sulfate therapy was initiated to prevent eclampsia. Pregnancy was terminated due to the worsening of the mother’s clinical condition, and feticide was performed at 15 + 1 weeks of gestation with a fetal intracardiac injection of 10% KCL, followed by uterine evacuation by hysterotomy. The contents of the cysts were aspirated due to the presence of large bilateral theca lutein cysts.

Macroscopic examination of the aspirated material showed the presence an enlarged molar mass and a male fetus (Fig. 5). The histopathology results were compatible with a second-trimester abortion and a complete hydatidiform mole, which was confirmed by p57kip2 immunohistochemistry (Neomarkers, Fremont, CA, USA), as shown in Fig. 6.

Weekly measurements of hCG were performed during the postmolar follow-up. In the third week after the uterine evacuation, the patient presented with three ascending

Fig. 3. A. Magnetic resonance imaging (MRI; coronal T1-weighted image) shows placental molar degeneration (*) and the fetus (arrow). B. MRI (coronal T2-weighted image) shows placental molar degeneration (*) and the fetus (arrow). C. Three-dimensional (3D) reconstruction from a T2-weighted true FISP sequence (coronal view) showing placental molar degeneration (*) and the fetus (arrow). D. An MRI (axial T2-weighted image) scan shows placental molar degeneration (*) and the fetus (arrow)
hCG measurements, which met the International Federation of Gynecology and Obstetrics (FIGO) criteria for GTN. The evaluation of GTN staging by chest computed tomography indicated the presence of three nodules >1.0 cm suggestive of pulmonary metastases, and the hCG level was 489,000 IU/L. Brain MRI was normal. Abdominal and pelvic MRI showed an enlarged uterus (160 × 68 × 80 mm, 452 cm³) and a heterogeneous myometrial mass measuring 6.0 cm, with an irregular contrast uptake similar to a tumor, which occupied the body and fundus of the uterus, and extended to the serosa, and was thus classified as stage III:7 (high risk for chemoresistance).

The patient underwent chemotherapy with the EMA/CO regimen (etoposide, methotrexate, actinomycin-D, cyclophosphamide, and oncovin), achieved remission after five cycles, and received three additional cycles of consolidation chemotherapy. At present, the patient remains under clinical, radiological and hormonal surveillance.

Discussion

Twin molar pregnancy is a rare obstetric event, characterized by the coexistence of a hydatidiform mole and a potentially viable fetus with a normal placenta, associated with several pregnancy complications, such as spontaneous abortions, intrauterine deaths, preeclampsia, and hyperthyroidism, potentially leading to an obstetric near miss(8,9).

Several singularities of this clinical case should be emphasized. The first are the serum hCG measurements at falsely low levels, characteristic for the high-dose Hook effect(10,11). Negative or falsely low hCG doses are a rare biochemical phenomenon present in patients with very high levels of hCG (usually >1,000,000 IU/L), which makes its correct measurement very hard, and may lead to a delay in the diagnosis of molar gestation. A simple dilution of the serum sample of 1:10 to 1:1000 could prevent this effect, and allow for the correct measurement of this biological marker of molar pregnancy. After this procedure was performed, the hCG level increased from 171 IU/L to 1,881,508 IU/L just two days later.

Another aspect to be considered is the occurrence of severe clinical complications, including hemorrhage, pre-eclampsia, and hyperthyroidism(12). High levels of hCG lead to TSH suppression, but stimulate the release of thyroid hormones, since the alpha subunit of hCG...
A twin pregnancy with a hydatidiform mole and a coexisting live fetus: prenatal diagnosis, treatment, and follow-up

Fig. 6. Photomicrography compatible with a complete hydatidiform mole at different magnifications, compatible with a total absence of p57kip2 (Neomarkers, Fremont, CA, USA) expression in villous stromal cells and the cytotrophoblast, which are a product of diandry

is homologous to the alpha subunit of TSH. In these cases, the screening of thyroid function and treatment with antithyroid drugs and beta-blockers is important to control the peripheral effects of hyperthyroidism, thus avoiding a thyrotoxic crisis.

The diagnosis of a twin molar pregnancy is clinically challenging. This condition needs to be differentiated from a partial hydatidiform mole, whose ultrasound diagnosis is challenging in the first trimester (sensitivity of 18% to 49%)\(^{13}\), and placental mesenchymal dysplasia, characterized by the presence of placentomegaly with multiple prominent cysts oriented perpendicularly to the choroidal plaque, without atypical trophoblastic proliferation\(^{14,15}\). A partial hydatidiform mole occurs with an unviable fetus, and thus gestation should be terminated. On the other hand, placental mesenchymal dysplasia and a twin molar pregnancy can coexist with the presence of a viable and normal fetus. In such cases, the pregnancy may be allowed to progress. Therefore, this differential diagnosis is crucial to prevent unnecessary pregnancy terminations.

Ultra-sonographic diagnosis of a twin pregnancy with a hydatidiform mole and a coexisting live fetus is feasible at the end of the first trimester\(^{16}\). MRI is essential to differentiate a twin pregnancy with a hydatidiform mole and a coexisting live fetus from a placental mesenchymal dysplasia, because the perinatal prognosis is favorable in the latter. Himoto \textit{et al.}\(^{17}\) evaluated three cases of twin pregnancy with a hydatidiform mole and a coexisting live fetus, as well as three cases of placental mesenchymal dysplasia. MRI showed that the twin pregnancy with a hydatidiform mole and a coexisting live fetus was located within an extrafetal sac accom-

panied by an intralesional and/or extralesional hemorrhage, while placental mesenchymal dysplasia was located within the placenta in the fetal sac without a hemorrhage. Wu \textit{et al.}\(^{18}\) described a case of twin pregnancy with a hydatidiform mole and a coexisting live fetus at gestational week 20, and MRI showed a distinct junction between the molar tissue and the myometrium, but no evidence of myometrial invasion, as in our case.

Cytogenetic analysis is crucial to diagnose a twin molar pregnancy. Chorionic villus biopsy combined with amniocentesis can obtain genetic material from the suspected placenta and the fetus with a normal appearance\(^{19}\). In the reported case, the sexual difference was fundamental to determine the different genetic origin of the conceptual products. For same-sex results, only the determination of the parental origin can help diagnose a complete hydatidiform mole. An interesting alternative for the evaluation of the parental genetic origin is the evaluation of the p57kip2 immunohistochemistry. The manifestation of p57kip2 is related to the genetic characterization of a paternal allele of maternal origin, and can be used in the differentiation between a complete and a partial hydatidiform mole\(^{20}\). Because a complete hydatidiform mole has an androgenetic origin, maternal alleles are not present in its genetic material, and thus complete moles do not express p57kip2. We observed that the immunohistochemical analysis of the placenta was negative for p57kip2, confirming its parthenogenetic single-parent origin, diploid by karyotype, and a clear case of complete hydatidiform mole.

The suspected or confirmed diagnosis of a twin pregnancy with a hydatidiform mole can lead to two strategies: elective termination of pregnancy due to the high risk to the mother, or comprehensive prenatal care in a Referral Center for GTD. A recent study on the predictors of fetal survival and taking home baby found that hCG levels up to 400,000 IU/L are the best indicators for a favorable perinatal outcome\(^8\). In fact, the occurrence of maternal complications before 20 weeks of gestation increases the chances for elective interruption of pregnancy\(^8\), and is associated with the occurrence of postmolar GTN\(^9\).

In cases in which elective termination of pregnancy is indicated, the technique used to perform this procedure should be chosen carefully, considering that uterine aspiration cannot be performed after the 12th week of gestation due to the presence of a fetal skeleton. In addition, the use of misoprostol in these molar pregnancies is associated with a greater likelihood of massive pulmonary trophoblastic embolization and a subsequent need for chemotherapy\(^{21,22}\). In the presented case, laparotomy was followed by hysterotomy, as there was no time for fetal elimination with misoprostol, considering the mother’s worsening clinical status.

Our patient recovered from surgery, and entered the postmolar follow-up with weekly measurements of se-
rum hCG levels under strict contraception\(^{1-5,23}\). Although the literature is not conclusive, most authors did not find a higher risk for postnatal GTN in women with a twin pregnancy with a hydatidiform mole\(^{5,9,24-26}\). However, the presence of common risk factors for the development of GTN, such as theca lutein cysts, elevated hCG levels, and clinical complications associated with a molar pregnancy also poses a risk for postmolar GTN\(^{59}\).

The treatment for postmolar GTN after a twin pregnancy with a hydatidiform mole followed the FIGO 2000 guidelines\(^{27}\). It should be noted that the cure rate of this neoplasia is \(>98\%\), even in the presence of multiple metastases, and treatment should occur at Referral Centers\(^{2,28,29}\).

**Conclusion**

Although rare, the occurrence of a twin pregnancy with a hydatidiform mole should be considered by obstetricians during prenatal care. Normal fetuses in the presence of a molar placenta should encourage diagnostic suspicion. Treatment at Referral Centers, in addition to providing imaging, pathology, and genetic resources for the preliminary analysis of these patients, facilitates systematic postmolar monitoring capable of anticipating disease progression to postnatal GTN and initiation of appropriate chemotherapy with a high chance of cure.

**Conflict of interest**

Authors do not report any financial or personal connections with other persons or organizations, which might negatively affect the contents of this publication and/or claim authorship rights to this publication.

**References**

1. Lurain JR: Gestational trophoblastic disease I: Epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol 2010; 203: 531–539.
2. Braga A, Uberti EM, Fajardo Mdo C, Viggiano M, Sun SY, Grillo BM et al.: Epidemiological report on the treatment of patients with gestational trophoblastic disease in 10 Brazilian referral centers: results after 12 years since International FIGO 2000 Consensus. J Reprod Med 2014; 59: 241–247.
3. Seckl MJ, Sebire NJ, Fisher RA, Goffler F, Massuger L, Sessa C et al.: Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl. 6): vi39–vi50.
4. Berkowitz RS, Golden DP. Current advances in the management of gestational trophoblastic disease. Gynecol Oncol 2013; 128: 3–5.
5. Lin LH, Maestá I, Braga A, Sun SY, Fushida K, Francisco RPV et al.: Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. Gynecol Oncol 2017; 145: 88–95.
6. Bajaj SK, Misra R, Gupta R, Nisha B, Thukral BB: Complete hydatidiform mole with coexisting twin fetus: usefulness of MRI in management planning. J Obstet Gynaecol India 2014; 64: 9–13.
7. Sun SY, Golden DP, Bernstein MR, Horowitz NS, Mattar R, Maestá I et al.: Maternal near miss according to World Health Organization classification among women with a hydatidiform mole: Experience at the New England Tropoblastic Disease Treatment Center, 1993–2013. J Reprod Med 2016; 61: 210–214.
8. Sukais M, Suwanrath C, Kor-Anantakul O, Geater A, Hanpraseuptong T, Atijamakul T et al.: Complete hydatidiform mole with co-existing fetus: predictors of live birth. Eur J Obstet Gynecol Reprod Biol 2017; 212: 1–8.
9. Sebire NJ, Foskett M, Paradinas FJ, Fisher RA, Francis RJ, Short D et al.: Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet 2002; 359: 2165–2166.
10. Nodler JL, Kim KH, Alvarez RD: Abnormally low hCG in a complete hydatidiform mole pregnancy: the hook effect. Gynecol Oncol Case Rep 2011; 1: 6–7.
11. Nigam A, Kumari A, Gupta N: Negative urine pregnancy test in a molar pregnancy: is it possible? BMJ Case Rep 2014; 2014.
12. Braga A, Moraes V, Maestá I, Amim Junior J, Rezende-Filho Jd, Elias K et al.: Changing trends in the clinical presentation and management of complete hydatidiform mole among Brazilian women. Int J Gynecol Cancer 2016; 26: 984–990.
13. Fowler DJ, Lindsay I, Seckl MJ, Sebire NJ: Routine pre-evacuation ultrasound diagnosis of hydatidiform mole: Experience of more than 1000 cases from a regional referral center. Ultrasound Obstet Gynecol 2006; 27: 56–60.
14. Starikov R, Goldman R, Dizon DS, Kostadinov S, Carr S: Placental mesenchymal dysplasia presenting as a twin gestation with complete molar pregnancy. Obstet Gynecol 2011; 118: 445–449.
15. Marusik C, Frykholm C, Ericson K, Wikström J, Axelsson O: Diagnosis of placental mesenchymal dysplasia with magnetic resonance imaging. Ultrasound Obstet Gynecol 2017; 49: 410–412.
16. Sheik S, Al-Riyami N, Mathew NR, Al-Sukaiti R, Qureshi A, Mathew M: Twin pregnancy with a complete hydatidiform mole and a coexisting live fetus: rare entity. Sultan Qaboos Univ Med J 2015; 15: 550–553.
17. Himoto Y, Kido A, Minamiguchi S, Moribata Y, Okumura R, Mogami H et al.: Prenatal differential diagnosis of complete hydatidiform mole with a twin live fetus and placental mesenchymal dysplasia by magnetic resonance imaging. J Obstet Gynecol Res 2014; 40: 1894–1900.
18. Wu TC, Shen SH, Chang SP, Chang CY, Guo WY: Magnetic resonance imaging of a twin pregnancy with a normal fetus and hydatidiform mole: a case report. J Comput Assist Tomogr 2005; 29: 415–417.
19. Marcorelles P, Audrezet MP, Le Bris MJ, Laurent Y, Chabaud JJ, Ferce C et al.: Diagnosis and outcome of complete hydatidiform mole coexisting with a live twin fetus. Eur J Obstet Gynecol Reprod Biol 2005; 118: 21–27.
20. Madi JM, Braga A, Paganella MP, Litvin IE, Da Ros Wendland EM: Accuracy of p57KIP2 compared with genotyping for the diagnosis of complete hydatidiform mole: Protocol for a systematic review and meta-analysis. Syst Rev 2016; 5: 169.
21. Royal College of Obstetricians and Gynaecologists: The Management of Gestational Trophoblastic Disease. Green-Top Guideline No. 38. RCOG 2010. Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/gt_38.pdf.
22. Tidy JA, Gillespic AM, Bright N, Radstone CR, Coleman RE, Hancock BW: Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol 2000; 78: 309–312.
23. Braga A, Maestá I, Short D, Savage P, Harvey R, Seckl MJ: Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review. BJOG 2016; 123: 1130–1135.
A twin pregnancy with a hydatidiform mole and a coexisting live fetus: prenatal diagnosis, treatment, and follow-up

24. Matsui H, Sekiya S, Hando T, Wake N, Tomoda Y: Hydatidiform mole coexistent with a twin live fetus: A national collaborative study in Japan. Hum Reprod 2000; 15: 608–611.

25. Massardier J, Golfier F, Journet D, Frappart L, Zalaquett M, Schott AM et al.: Twin pregnancy with complete hydatidiform mole and coexistent fetus: obstetrical and oncological outcomes in a series of 14 cases. Eur J Obstet Gynecol Reprod Biol 2009; 143: 84–87.

26. Niemann I, Sunde L, Petersen LK: Evaluation of the risk of persistent trophoblastic disease after twin pregnancy with diploid hydatidiform mole and coexisting normal fetus. Am J Obstet Gynecol 2007; 197: 45.e1–45.e5.

27. Ngan HY, Bender H, Benedet JL, Jones H, Montruccoli GC, Pecorelli S et al.: Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet 2003; 83: 175–177.

28. Kohorn EI: Worldwide survey of the results of treating gestational trophoblastic disease. J Reprod Med 2014; 59: 145–153.

29. Dantas PR, Maestá I, Cortés-Charry R, Growdon WB, Braga A, Rudge MV et al.: Influence of hydatidiform mole follow-up setting on postmolar gestational trophoblastic neoplasia outcomes: a cohort study. J Reprod Med 2012; 57: 305–309.